Needham & Company LLC Has Lowered Expectations for Autolus Therapeutics (NASDAQ:AUTL) Stock Price

Autolus Therapeutics (NASDAQ:AUTL) had its price target reduced by equities research analysts at Needham & Company LLC from $11.00 to $10.00 in a research note issued to investors on Monday,Benzinga reports. The firm presently has a “buy” rating on the stock.

A number of other research firms have also issued reports on AUTL. Weiss Ratings reissued a “sell (d-)” rating on shares of Autolus Therapeutics in a report on Wednesday, October 8th. William Blair reaffirmed an “outperform” rating on shares of Autolus Therapeutics in a report on Wednesday, September 24th. Finally, Wall Street Zen cut shares of Autolus Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Saturday, November 15th. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Autolus Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $8.33.

Autolus Therapeutics Trading Down 13.0%

Shares of AUTL stock traded down $0.24 on Monday, reaching $1.58. 2,385,122 shares of the stock were exchanged, compared to its average volume of 2,165,066. The company has a market capitalization of $419.18 million, a price-to-earnings ratio of -1.90 and a beta of 2.01. The business’s 50 day moving average price is $1.56 and its 200 day moving average price is $1.77. Autolus Therapeutics has a twelve month low of $1.11 and a twelve month high of $2.70.

Autolus Therapeutics (NASDAQ:AUTL) last released its quarterly earnings data on Wednesday, November 12th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.07). Autolus Therapeutics had a negative return on equity of 63.76% and a negative net margin of 439.69%.The business had revenue of $21.19 million for the quarter, compared to analyst estimates of $21.08 million. Equities research analysts forecast that Autolus Therapeutics will post -0.94 earnings per share for the current year.

Institutional Investors Weigh In On Autolus Therapeutics

Large investors have recently modified their holdings of the stock. Marex Group plc acquired a new position in shares of Autolus Therapeutics in the 2nd quarter valued at about $28,000. Caitong International Asset Management Co. Ltd bought a new position in Autolus Therapeutics during the 3rd quarter valued at $46,000. R Squared Ltd acquired a new stake in Autolus Therapeutics in the 2nd quarter valued at about $50,000. Invesco Ltd. grew its position in Autolus Therapeutics by 53.3% in the first quarter. Invesco Ltd. now owns 32,738 shares of the company’s stock worth $51,000 after buying an additional 11,381 shares during the last quarter. Finally, Delaney Dennis R bought a new stake in shares of Autolus Therapeutics during the 2nd quarter worth $55,000. Institutional investors and hedge funds own 72.83% of the company’s stock.

Autolus Therapeutics Company Profile

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.